PHARMACEUTICAL/PBM PROMOTIONS TO MANAGED CARE: IMPACT ON FDA REGULATION, INDEPENDENCE IN FORMULARY DECISION-MAKING WILL BE TOPICS OF PUBLIC MEETING
FDA wants to assess the knowledge and sophistication of managed care buyers to help the agency revise its role in regulation of drug promotional activities. FDA is asking specifically for information on the sophistication of the managed care market in the proposed agenda for an open meeting on promotional issues scheduled for Oct. 19-20.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth